Catalent Invests $40 Million to Increase Patient-Centric Dose Form Manufacturing Capabilities at Winchester, Kentucky

Share Article

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is investing up to $40 million at its manufacturing facility in Winchester, Kentucky. The investment will see the installation of new equipment that will increase the site’s formulation and controlled-release tablet and capsule manufacturing capabilities, and capacity.

Our Winchester facility provides customers with a high degree of flexible manufacturing solutions and has a proven track record of success with technology transfers and product launches.

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is investing up to $40 million at its manufacturing facility in Winchester, Kentucky. The investment will see the installation of new equipment that will increase the site’s formulation and controlled-release tablet and capsule manufacturing capabilities, and capacity.

New technologies that are included in the investment include a laser drill for osmotic drug delivery, stick pack dosage manufacturing capabilities, and roller compaction and fluid bed capacity will be increased at the site. Additionally, a spray dryer, used to create amorphous solid dispersions and overcome formulation challenges posed by poorly soluble drugs, will be installed to provide commercial scale up capacity for projects that progress from early stage development, and allow tech transfer of projects from Catalent’s development sites including San Diego and Nottingham, U.K.

An automated bottling line is also currently being installed, and completion of the various equipment validations is expected over the coming months.

“Our Winchester facility provides customers with a high degree of flexible manufacturing solutions and has a proven track record of success with technology transfers and product launches,” commented Rick Tucker, General Manager, Catalent Winchester. “We have a clear investment strategy at the site that is not only driven by immediate customer needs, but also looks to the future in anticipation of demand and new technologies.”

Opened in 1992, Catalent’s Winchester facility has evolved into one of the industry’s premier sites for advanced oral controlled-release drug formulation and manufacturing. The site has produced over three-billion tablets and capsules annually and launched more than 100 new products into the market since its inception. The site underwent a $35M facility investment in 2015 that doubled its footprint to 180,000 square feet.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling
Catalent
+44 7580 041073
Email >

Richard Kerns
Visit website